“Dear Doctor” Letter Cautions About Cardiopulmonary Events With NeutroSpec
This article was originally published in The Pink Sheet Daily
Executive Summary
Letter from Mallinckrodt and Palatin alerts healthcare providers to serious cardiopulmonary events that may occur within minutes of injection with the imaging agent.
You may also be interested in...
NeutroSpec Pulled From The Market
FDA "reconsidered" the risk/benefit balance for Mallinckrodt/Palatin Technologies' appendicitis imaging agent, which has been associated with cardiopulmonary events.
NeutroSpec Pulled From The Market
FDA "reconsidered" the risk/benefit balance for Mallinckrodt/Palatin Technologies' appendicitis imaging agent, which has been associated with cardiopulmonary events.
Palatin/Mallinckrodt Neutrospec Clears FDA; Imaging Agent Available In Mid-August
The radiolabeled monoclonal antibody is approved for diagnosing equivocal appendicitis. Palatin expects to initiate a Phase III trial for diagnosing osteomyelitis by the first quarter of 2005.